Monthly Review: Journal of Diabetes Investigation (Vol. 12, Issue 10)
This issue of the Journal of Diabetes Investigation highlights crucial clinical advancements across the spectrum of diabetes care. Key themes include identifying rare genetic subtypes of diabetes, simplifying daily management strategies to improve patient quality of life, and recognizing early cardiovascular and metabolic risk factors.
From breakthroughs in diagnostic biomarkers to real-world applications of technology like continuous glucose monitors (CGM), these studies offer valuable insights that help doctors tailor more personalized and effective treatments for patients and their families.
This article was created with the assistance of AI. Although the content is based on original research articles and other academic sources, errors may be present. Please verify the information using the original articles and consult qualified healthcare professionals for medical advice.
A novel RFX6 heterozygous mutation (p.R652X) in maturity‐onset diabetes mellitus: A case report
Authors: Sakiho Imaki, Katsumi Iizuka, Yukio Horikawa, et al.
Research Objective: To investigate a potential genetic cause of maturity-onset diabetes of the young (MODY) in a young female patient.
Methods: Researchers performed genetic testing on a 16-year-old female diagnosed with diabetes, alongside her mother and brother. They analyzed her physical responses to meals and checked for diabetes-related autoantibodies.
Main Findings: Testing revealed a brand-new genetic mutation in the RFX6 gene (p.R652X) shared by the patient, her mother, and her brother. The patient had no typical autoantibodies (which rule out classic type 1 diabetes) and showed a lower-than-normal release of insulin and gut hormones (GLP-1 and GIP) after eating.
Clinical Significance: This case confirms that a single-copy mutation in the RFX6 gene is a distinct cause of MODY. It expands our genetic map of diabetes and helps doctors identify patients who may have this specific form of hereditary diabetes.
- MODY is a rare, inherited form of diabetes that is different from both Type 1 and Type 2 diabetes.
- If you are diagnosed with diabetes at a young age and have a family history of diabetes, genetic testing can help determine the exact cause and guide treatment.
Effectiveness of remote continuous glucose monitoring on adverse outcomes among patients with diabetes complicated with COVID‐19
Authors: Yun Shen, Lei Zhang, Xiaohong Fan, Jian Zhou
Research Objective: To evaluate whether using remote continuous glucose monitoring (CGM) improves health outcomes for hospitalized diabetes patients who also have COVID-19.
Methods: This prospective study tracked patients with diabetes and COVID-19 who used an intermittently scanned CGM system to monitor their blood sugars.
Main Findings: Patients who used the CGM system experienced significantly better clinical outcomes during their COVID-19 illness compared to those who did not.
Clinical Significance: Utilizing modern CGM technology offers a safe and highly effective way to manage glucose levels during acute infectious illnesses, keeping both patients and healthcare providers safer.
- Managing blood sugar closely is incredibly important when fighting off an infection like COVID-19.
- Continuous glucose monitors can provide real-time blood sugar trends, helping you and your healthcare team make safer decisions without needing frequent finger-pricks.
Risk of early mortality and cardiovascular disease according to the presence of recently diagnosed diabetes and requirement for insulin treatment: A nationwide study
Authors: You‐Bin Lee, Kyungdo Han, Bongsung Kim, et al.
Research Objective: To evaluate the risks of heart attack, stroke, and early death in people recently diagnosed with type 2 diabetes, based on whether they require insulin treatment.
Methods: A large population study analyzing health data from 363,919 Korean adults over 40 years old, followed for an average of 7.8 years.
Main Findings: Newly diagnosed patients had increased risks of heart attack, stroke, and early death compared to those without diabetes. This risk was particularly high in patients who required early insulin treatment. For example, those on insulin had a 2.3 times higher risk of a heart attack and a 3.0 times higher risk of early death than people without diabetes.
Clinical Significance: Early insulin use in type 2 diabetes may identify patients with more aggressive disease who require highly intensive, protective cardiovascular care right from their diagnosis.
- A diabetes diagnosis means taking extra care of your heart, not just your blood sugar.
- If you have been diagnosed with type 2 diabetes and need to start insulin early on, talk to your doctor about heart-protective strategies like managing blood pressure and cholesterol.
Association between influenza and the incidence rate of new‐onset type 1 diabetes in Japan
Authors: Yuichi Nishioka, Tatsuya Noda, Sadanori Okada, et al.
Research Objective: To investigate whether getting sick with influenza is linked to a higher risk of developing type 1 diabetes.
Methods: A retrospective study in Japan that analyzed health database records from 10,400 patients who developed new-onset type 1 diabetes.
Main Findings: The study found that individuals had a 1.3-fold higher risk of developing type 1 diabetes in the 180 days following an influenza diagnosis compared to other times of the year.
Clinical Significance: This suggests that the influenza virus could potentially act as an environmental trigger for the development of type 1 diabetes. However, more research is needed to understand the exact biological mechanisms behind this link.
- While the overall risk remains low, viral infections like the flu may play a role in triggering autoimmune conditions like type 1 diabetes.
- Staying up to date with your annual flu vaccine is an important way to protect your overall health.
Simplification of complex insulin regimens using canagliflozin or liraglutide in patients with well‐controlled type 2 diabetes: A 24‐week randomized controlled trial
Authors: Yasuyo Ando, Fumika Shigiyama, Takahisa Hirose, Naoki Kumashiro
Research Objective: To determine if type 2 diabetes patients who are well-controlled on complex, multiple-daily insulin injections can successfully switch their mealtime (bolus) insulin to once-daily medications.
Methods: In a 24-week clinical trial, 40 well-controlled patients (HbA1c < 7.5%) stopped their mealtime insulin and instead took either canagliflozin (a daily pill) or liraglutide (a daily non-insulin injection), while continuing their background (basal) insulin.
Main Findings: Both groups successfully maintained stable blood sugar levels without any severe low blood sugar episodes. In addition, patients were able to decrease their overall daily insulin dose and reported a significant boost in their quality of life, which was directly related to having fewer injections per day.
Clinical Significance: Complex multiple-daily injection regimens can be simplified safely in many patients, helping to reduce treatment burden while maintaining excellent glucose control.
- If you are currently taking multiple insulin shots a day to manage your type 2 diabetes, you may not have to do this forever.
- Discuss with your doctor whether you might be a candidate for newer, once-daily non-insulin medications to reduce your daily injection burden and improve your quality of life.
Nonalcoholic fatty liver disease is a risk factor for glucose intolerance onset in men regardless of alanine aminotransferase status
Authors: Teruki Miyake, Bunzo Matsuura, Shinya Furukawa, et al.
Research Objective: To clarify whether having fatty liver disease (FLD) increases the risk of developing prediabetes (impaired fasting glucose), even in people who have normal liver enzymes.
Methods: Researchers retrospectively evaluated health data from 8,664 participants who completed more than two annual health exams, classifying them by sex, alcohol use, liver enzymes (ALT), and fatty liver status.
Main Findings: For nonalcoholic men and women, fatty liver disease was a strong, independent risk factor for developing prediabetes, even when their liver enzymes (ALT) were in the completely normal range.
Clinical Significance: Simply having a "normal" liver blood test does not mean you are in the clear. Fatty liver itself is a metabolic warning sign, making it critical to address fatty liver early on to prevent the development of diabetes.
- A routine normal liver enzyme blood test is not enough to rule out metabolic risk if you have been told you have a fatty liver.
- Focusing on healthy eating, exercise, and weight management is essential to protect both your liver and your metabolic health.
Human SHC‐transforming protein 1 and its isoforms p66shc: A novel marker for prediabetes
Authors: Herbert F Jelinek, Charlotte Helf, Kinda Khalaf
Research Objective: To investigate if the biomarker p66shc (related to cell stress) can be used to improve the sensitivity and accuracy of routine prediabetes screenings.
Methods: A cross-sectional study involving 346 participants who completed a health screening. Researchers compared the predictive accuracy of standard HbA1c tests alone to newer multidimensional models that include stress and inflammatory markers.
Main Findings: People with prediabetes had significantly lower levels of p66shc. While testing HbA1c alone was only 62% accurate in identifying prediabetes, adding p66shc and triglycerides boosted the diagnostic accuracy to an impressive 88.05%.
Clinical Significance: Combining cellular stress biomarkers with standard blood sugar markers could dramatically improve early prediabetes detection, allowing patients to begin prevention strategies much sooner.
- Standard blood sugar tests like HbA1c can sometimes miss early-stage prediabetes.
- In the future, adding specific stress and inflammatory markers to standard blood draws could help doctors find and help treat prediabetes years before it develops further.
